The problem with blocking D2

At the circuit level, schizophrenia is characterized by an imbalance between cortical excitatory glutamatergic and inhibitory GABAergic signaling, which disrupts basic cortical information processing and is thought to produce the core symptoms of the illness.

Traditional antipsychotics act primarily by blocking dopamine D2 receptors, mitigating the downstream effects of excessive dopamine signaling. The dominant hypothesis holds that hyperdopaminergia within mesolimbic pathways underlies positive symptoms: hallucinations, delusions, disorganized thought. D2 blockade addresses that, and for many patients it addresses it well.

The difficulty is that dopaminergic dysregulation in schizophrenia is not uniformly excessive. Hypodopaminergic states in the frontal cortex have been implicated in cognitive impairment and in negative symptoms. A drug that blocks D2 receptors indiscriminately cannot correct a system that is overactive in one region and underactive in another. It controls positive symptoms while leaving the broader abnormality untouched.

Working upstream instead

Muscarinic modulation offers a different point of entry. Rather than blocking the receptor at the end of the pathway, xanomeline trospium acts on the circuits that govern dopamine release in the first place.

The two relevant receptor subtypes do different jobs:

• M4 receptors, located subcortically, reduce presynaptic dopamine release when activated. This is the primary route to control of positive symptoms.
• M1 receptors, enriched in frontal cortical excitatory circuits, may improve negative symptoms and potentially address cognitive impairment, correcting aberrant dopaminergic signaling through top-down executive control.

The trospium component does not cross into the brain. Its job is peripheral antagonism, limiting the cholinergic side effects that made earlier muscarinic agonists intolerable.

The prefrontal hypothesis

A second mechanism may matter as much as the dopaminergic one. Prefrontal cortex hypofunction in schizophrenia is well documented on functional neuroimaging, and its origins have been attributed to neurodevelopmental mechanisms including excessive synaptic pruning in adolescence.

Because the prefrontal cortex is a major source of top-down executive control, its reduced output is thought to drive widespread circuit dysregulation, including the aberrant dopaminergic activity described above. The prefrontal cortex also plays a central role in motivational drive. That makes M1-mediated activation a plausible explanation for the effect on negative symptoms that panelists describe seeing in practice, and which the trial data support.

What the EMERGENT trials showed

EMERGENT-1, -2, and -3 were randomized, double-blind, placebo-controlled, five-week inpatient studies in adults aged 18 to 60 with schizophrenia who had experienced an acute exacerbation of positive symptoms requiring hospitalization within the prior two months. The primary endpoint was change from baseline in PANSS total score.

Pooled post-hoc analysis showed statistically significant improvement in PANSS total and positive subscale scores versus placebo, with separation evident at the first assessment and widening through the end of the study.

Negative symptoms behaved differently. Reductions on PANSS negative scores and the Marder negative factor emerged more gradually, with numerical differences appearing early but not reaching statistical significance until week 3. CGI-S scores separated by week 2 and improved progressively through completion.

That two-speed pattern is the clinically useful finding. Positive symptoms respond early. Negative symptoms take longer and keep improving. A clinician who judges the drug at week 2 is judging half of it.

Tolerability, and one practical detail

Across the pooled EMERGENT studies, discontinuation rates were similar between groups, 27.6% for xanomeline trospium versus 22.7% for placebo. Treatment-emergent adverse events were more common with active treatment, 67.9% versus 51.3%, and were largely gastrointestinal, generally mild to moderate. Rates of extrapyramidal symptoms, somnolence, and weight gain remained low in both groups.

One detail from the trial protocol carries directly into practice: xanomeline trospium was taken on an empty stomach. Trospium is poorly absorbed with food, and taking the drug after a meal raises peripheral trospium exposure. Nausea and vomiting can be problematic if it is administered after a patient has eaten.

Durability

Two 52-week open-label extensions followed. EMERGENT-4 enrolled patients completing the double-blind studies regardless of original assignment; EMERGENT-5 enrolled patients naive to the drug.

In EMERGENT-4, improvement in PANSS total score was evident by week 2 and sustained through week 52. By the end, 68.6% of participants achieved at least 30% improvement from baseline and 37.1% achieved at least 50%. Among those continuing from active treatment in the parent study, 73.7% reached the 30% threshold, compared with 62.5% of those switched from placebo. CGI-S improvement of at least one point was seen in 82.9% of the population, and 42.9% reached a CGI-S of 3 or lower, indicating mild illness severity.

Just over half of participants reported at least one treatment-emergent adverse event. The most frequent anticholinergic events were dry mouth (17.8%), constipation (9.9%), and dyspepsia (8.6%). Common procholinergic events were nausea (10.5%), vomiting (6.6%), and diarrhea (5.9%). These typically arose within the first two weeks, were self-limited, and rarely led to discontinuation.

Panel consensus

Xanomeline trospium should be considered early in the treatment course for appropriate patients. It shows efficacy against both positive and negative symptoms and may support functional improvement and cognitive preservation. These benefits are especially relevant in first-episode psychosis and early-stage illness, where intervention may alter the trajectory of the disease. Because schizophrenia requires lifelong treatment, starting with a well-tolerated agent may reduce the burden of long-term complications and support sustained functional recovery.

The dosing is the easy part

Xanomeline trospium comes in three fixed-dose combinations: a starting dose of 50 mg/20 mg and two maintenance doses, 100 mg/20 mg and 125 mg/30 mg. All doses are taken twice daily, in the absence of food.

The panel reached consensus on a straightforward outpatient schedule:

1. Weeks 1 to 2. Begin at 50 mg/20 mg twice daily. Assess efficacy and tolerability at the first follow-up, ideally in person, to monitor both symptom change and side effects closely.
2. If well tolerated. Increase to 100 mg/20 mg, with follow-up scheduled according to the patient’s care plan, typically within 2 to 12 weeks.
3. If still well tolerated. Increase to 125 mg/30 mg, again with follow-up per the care plan.

That is the whole titration. What the panel spent its time on was the scaffolding around it.

Fill the prescription the same day

The panel emphasized timely initiation, recommending that patients fill their prescription immediately after the appointment so treatment can begin that same evening.

This sounds like a minor logistical note. In a population where the gap between a prescription written and a prescription started is a well-documented failure point, it is not. The recommendation is to close that gap to hours.

Assume the nausea

The most common reason patients stop is gastrointestinal, and it arrives early. The panel’s position is that this should be managed prospectively rather than reactively, with antiemetic support offered at initiation rather than after the first bad week.

Two points to cover in counseling, both of which change outcomes:

• Dosing on an empty stomach is not optional. Trospium is poorly absorbed with food. Taking the dose after a meal increases peripheral exposure and makes nausea and vomiting considerably more likely. This is the single most common avoidable cause of early intolerance.
• The side effects wane. Anticholinergic and procholinergic effects typically arise within the first two weeks, are self-limited, and rarely lead to discontinuation in patients who are prepared for them. A patient who expects two uncomfortable weeks behaves very differently from one who is surprised by them.

What to monitor

The panel’s third consensus statement addresses the adverse event profile directly:

Most clinically relevant adverse events associated with xanomeline trospium are anticholinergic; proactive management is key. Monitor for urinary retention, dry mouth, and constipation. Discontinue or minimize additive burden from other anticholinergic agents.

That last clause deserves attention in outpatient practice, where patients frequently arrive on a regimen assembled over years. Benztropine, first-generation antihistamines, tricyclics, and bladder antimuscarinics all add to the same burden. The cumulative load, not the new drug in isolation, is what produces urinary retention.

Where it fits in the course of illness

The panel’s view is that this agent belongs early, not late. The reasoning runs through tolerability rather than efficacy: schizophrenia requires lifelong treatment, and the long-term complications of dopamine blockade, including metabolic burden, extrapyramidal symptoms, and tardive dyskinesia, are dose related and cumulative.

Beginning with an agent that does not carry metabolic dysregulation, weight gain, prolactin elevation, or extrapyramidal symptoms changes what the next twenty years of treatment cost the patient. In first-episode psychosis in particular, the panel considered that a reason to lead with it rather than reserve it.

Why the ward changes the calculus

Patients admitted for inpatient care are frequently acutely decompensated, often having discontinued their medication before hospitalization. Rapid control of symptoms matters for the safety of the patient, the staff, and anyone else who comes into contact with them.

Gradual titration is poorly suited to a stay measured in days. Dr Halassa recommended a faster strategy, closer to the one used in the EMERGENT trials, escalating to 100 mg/20 mg or 125 mg/30 mg by day 2 or 3 of hospitalization.

Two features of inpatient care make that acceleration reasonable rather than reckless:

• Adverse events can be caught quickly. Twenty-four-hour nursing support and daily prescriber oversight mean a developing problem is identified in hours rather than at the next appointment.
• Supportive medication is actually administered. Antiemetic support at initiation is a recommendation in the clinic and a reliable fact on the ward. The same is true of dosing on an empty stomach, which requires coordination with meal service but is enforceable in a way it is not at home.

The negative symptom observation

The panel’s clinical experience converged on something the trial data show more slowly: meaningful early change in negative symptoms and overall illness severity.

This is worth separating from the trial finding. In EMERGENT, negative symptom improvement did not reach statistical significance until week 3. What panelists describe seeing inpatient is a brightening of affect and social engagement within days. Those are not the same measurement, and the clinical observation is uncontrolled. But it is consistent across panelists and it shapes how they use the drug.

Real-world data from a treatment-resistant population

Dr Halassa reported a retrospective analysis of 49 hospitalized patients with chronic, treatment-resistant psychotic disorders. Approximately half showed clinically meaningful improvement after initiation.

Computational clustering and discriminant analyses identified the predictors:

• Positive predictors of response: prominent negative symptoms, and a history of stimulant use.
• Negative predictor: intellectual disability.

That pattern echoes the panel’s broader clinical experience. It suggests a role in stimulant-associated psychosis, and limited utility in neurodevelopmental subgroups. For an acutely decompensated inpatient with a negative-symptom-dominant presentation, it is a reason to consider the drug early in the admission rather than after other options have failed.

Combination in practice

Many inpatients are well into their illness course and arrive on high doses of second-generation antipsychotics, frequently on complex polypharmacy regimens.

In Dr Halassa’s practice, xanomeline trospium is often combined with an atypical antipsychotic to reach sufficient stabilization for discharge. His clinical experience suggests the combination may be antipsychotic dose-sparing: pairing it with a lower dose of an atypical has provided effective symptom control while reducing reliance on higher doses of the dopamine blocker.

If that holds, the long-term implication is significant, because the adverse effects that accumulate over a treatment lifetime, metabolic burden, extrapyramidal symptoms, and tardive dyskinesia, are dose related.

Discharge is part of the initiation

The panel treated discharge planning as continuous with starting the drug rather than as a separate administrative step.

Collaboration with case managers, social workers, therapists, and nursing staff supports continuity and reinforces adherence. Patients and their care team should be counseled on the practical requirements, particularly the fasting rule and the expected early side effects.

The panel agreed on one concrete requirement: every patient should have a follow-up appointment scheduled with their regular psychiatrist before discharge. A rapid inpatient response is worth little if the first outpatient contact is weeks away.

Two different reasons to switch

Side effect burden is among the most commonly cited reasons for discontinuation and nonadherence in serious mental illness. When side effects become intolerable, a clinician-guided taper is strongly preferred over abrupt discontinuation, which carries risk of dopamine hypersensitivity and rebound psychosis.

Because xanomeline trospium is not associated with metabolic dysregulation, weight gain, prolactin elevation, or extrapyramidal symptoms, it is a reasonable destination for patients whose recovery is being limited by the side effects of their current regimen.

The second reason is unresolved symptoms. Patients with longer illness duration often continue to experience breakthrough positive or negative symptoms, or persistent cognitive impairment, despite adherence. Cross-titration may be considered when a patient remains symptomatic on an antipsychotic they are actually taking.

An honest note on the evidence

In clinical development, xanomeline trospium was studied as monotherapy. There is little published information on combining it with an antipsychotic.

The panel was explicit about this gap. Where a polypharmacy approach is necessary, they considered it a good candidate for add-on therapy on the strength of its distinct mechanism and differentiated side effect profile, but that is reasoning from pharmacology and clinical experience, not from trial data.

Taper by pharmacologic class

The panel’s central practical recommendation is that the taper should be structured around the class of antipsychotic the patient is currently taking. Patients begin the 50 mg/20 mg starting dose the same evening they are seen, while the existing agent is tapered according to its class:

• The “dones” (risperidone, paliperidone) can often be tapered over several days with minimal withdrawal risk.
• The “pines” (quetiapine, olanzapine, clozapine) require a slower taper, over one to three weeks, to prevent rebound sedation or insomnia.
• The “azoles”, D2 partial agonists (aripiprazole, brexpiprazole, cariprazine), may generally be discontinued more quickly given their long half-lives.

Where the rationale for switching is unresolved symptoms rather than side effects, the panel recommends discontinuing the current antipsychotic while initiating xanomeline trospium, with close monitoring during the transition. If decompensation occurs, the antipsychotic should be reintroduced.

The dose-sparing observation

The panel’s most consequential clinical observation concerns combination rather than replacement. In their experience, xanomeline trospium at 100 mg/20 mg to 125 mg/30 mg combined with a low dose of an atypical antipsychotic has often provided better symptom control than either alone at higher dose.

If the effect is real, the benefit compounds over time. The movement disorders and metabolic complications that accumulate across a treatment lifetime are dose related, so a regimen that achieves control at a lower dopamine-blocking dose reduces cumulative exposure without sacrificing efficacy.

Long-acting injectables

Concomitant use with a long-acting injectable requires a tailored approach. The panel’s position is that using xanomeline trospium in a patient on a maintenance LAI dose may allow a reduction in that LAI dose once the new agent has stabilized.

The goal is the same as in the oral combination: better symptom control while minimizing cumulative dopamine receptor burden.

Counseling during the transition

Patient counseling remains critical through a cross-titration. Two messages carry most of the weight, and both are the same ones that matter at initiation:

• Take it on an empty stomach, to optimize trospium absorption and limit gastrointestinal effects.
• The early side effects tend to wane.

A patient going through a taper and an initiation simultaneously has more to keep track of and more opportunities to conclude the new drug is not working. Setting expectations before the transition begins is what keeps them in it.